Alvaro Aranda Rodriguez, MD
Pulmonary Disease · Guaynabo, PRNPI 1972587970
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $619,150 of the $724,520 with a category attached, or 85.5%. It is spread thinly across 35 manufacturers, the largest accounting for just 19.7%. Among pulmonary disease clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,148 payments — averaging $631.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$143K
- Bayer$132K
- Actelion Pharmaceuticals US, Inc.$114K
- Sanofi$83K
- Mallinckrodt Hospital Products Inc.$78K
- Mylan Specialty L.p.$45K
- plus $130K from 29 others
Across 329 payments — averaging $3453.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$291K
- Boehringer Ingelheim$155K
- GSK$136K
- Regeneron$103K
- Actelion Pharmaceuticals, Ltd$100K
- AstraZeneca$81K
- plus $270K from 13 others
What the payments were for
- Consulting fees$41,4186%
- Speaking & faculty fees$619,15085%
- Travel & lodging$31,3044%
- Food & beverage$31,9374%
- Education$7110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 215 | $142,557 |
| Bayer | 112 | $131,935 |
| Actelion Pharmaceuticals US, Inc. | 147 | $114,285 |
| Sanofi | 85 | $82,760 |
| Mallinckrodt Hospital Products Inc. | 47 | $77,919 |
| Mylan Specialty L.p. | 96 | $45,119 |
| Mallinckrodt Enterprises LLC | 26 | $34,195 |
| Merck | 47 | $21,825 |
| Boehringer Ingelheim | 47 | $20,214 |
| Grifols USA, LLC | 28 | $19,409 |
| Genentech USA, Inc. | 31 | $16,735 |
| Insmed, Inc. | 10 | $4,600 |
| AstraZeneca | 72 | $3,810 |
| Viatris Specialty LLC | 12 | $2,604 |
| E.r. Squibb & Sons, L.L.C. | 4 | $1,610 |
| GSK | 48 | $1,471 |
| Johnson & Johnson | 27 | $569 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $435 |
| Genentech, Inc. | 7 | $397 |
| Amgen | 14 | $328 |
| Shire North American Group Inc | 5 | $274 |
| ANI Pharmaceuticals, Inc. | 10 | $247 |
| Boston Scientific | 4 | $200 |
| Harmony Biosciences LLC | 5 | $172 |
| Jazz Pharmaceuticals Inc. | 4 | $153 |
| Mylan LLC | 10 | $130 |
| Lilly USA, LLC | 1 | $125 |
| Sanofi-aventis U.S. LLC | 5 | $114 |
| Eli Lilly Export S.A. Puerto Rico Branch | 4 | $98 |
| Teva Pharmaceuticals USA, Inc. | 3 | $84 |
| Sandoz | 2 | $45 |
| Gilead | 2 | $41 |
| PBG Puerto Rico LLC | 1 | $28 |
| Biocryst US Sales Co., LLC | 1 | $27 |
| Bayer Puerto Rico Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$130,579
- ACTHAR$111,176
- UPTRAVI$102,725
- OPSUMIT$101,400
- DUPIXENT$89,754
- TYVASO$69,475
- Yupelri$46,023
- ORENITRAM$38,969
- REMODULIN$32,088
- Prolastin-C Liquid$12,609
- NONE$11,481
- XOLAIR$9,234
- Esbriet$6,874
- WINREVAIR$6,693
- Prolastin-C$6,502
- Arikayce$4,132
- OFEV$4,008
- PNEUMOVAX 23$2,625
- STIOLTO RESPIMAT$1,545
- OPDIVO$1,526
How this compares
$724,520 in reported general payments places this provider in the 95th percentile of 138 pulmonary disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 942 | $12,599,986 |
| OpsumitMacitentan | 674 | $8,535,776 |
| Tyvaso DpiTreprostinil | 159 | $3,656,135 |
| UptraviSelexipag | 65 | $1,535,404 |
| OfevNintedanib Esylate | 85 | $1,076,328 |
| Orenitram ErTreprostinil Diolamine | 60 | $941,221 |
| OpsynviMacitentan/Tadalafil | 30 | $378,605 |
| EsbrietPirfenidone | 35 | $367,031 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 475 | $320,228 |
| Dupixent SyringeDupilumab | 53 | $201,246 |
| LetairisAmbrisentan | 12 | $155,611 |
| Spiriva RespimatTiotropium Bromide | 289 | $155,186 |
| Dupixent PenDupilumab | 39 | $148,254 |
| Pirfenidone | 56 | $123,261 |
| Ambrisentan | 69 | $114,153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $131,935 | $12,599,986942 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Opsynvi | $114,285 | $10,449,786769 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $20,214 | $1,259,632432 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Arnuity Ellipta | $1,471 | $522,512840 claims |
| Genentech USA, Inc.Esbriet | $16,735 | $367,03135 claims |
| GileadLetairis | $41 | $155,61112 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $3,810 | $92,681302 claims |
| Johnson & JohnsonXarelto | $569 | $7,72514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 138 pulmonary disease providers in Puerto Rico.
Other pulmonary disease in Guaynabo
- Elba Martin ReyesGuaynabo$10K
- Jonathan Torrens OlanGuaynabo$10K
- Maria Betancourt QuilesGuaynabo$6K
- Kimberly Padilla RodriguezGuaynabo$5K
- Jonathan Torres LunaGuaynabo$3K
- Luis Garcia BarretoCoamo$393K
- Luis Nieves GarrasteguiRio Piedras$121K
- Jahaira Serrano DominguezArecibo$102K
- William Villanueva-BosqueArecibo$67K
- Domingo Chardon FelicianoPonce$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.